

Your brand of bisoprolol is changing

Ipca-Bisoprolol is your new brand



Between 1 November 2023 and 1 April 2024, your pharmacist will change your brand of bisoprolol from Bisoprolol Mylan or Viatris to Ipca-Bisoprolol.

What's changed?

Your brand of bisoprolol is changing from Bisoprolol Mylan or Viatris to Ipca-Bisoprolol.

Your tablet will be a different shape and the packaging will change.

Why is this happening?

Pharmac runs an annual tender on many of the medicines we fund. This tender gives suppliers an opportunity to offer already funded products for better, more competitive prices. The savings we make through the tender process frees up money so we can fund new treatments for people.

This brand change is helping us fund more medicines for better health outcomes for all New Zealanders.

Your medicine has been carefully assessed


Medsafe has assessed Ipca-Bisoprolol for safety, effectiveness, and quality. It meets the same standards as the Mylan and Viatris brands. It is approved for use in New Zealand.

Ipca-Bisoprolol works the same way

Ipca-Bisoprolol has the same active ingredient as your current brand and is delivered to the body in the same way.

This means your new brand of medicine works the same as your old brand. You shouldn't notice any difference in how it affects you.

The only difference is the look.



Not shown to scale

Questions?

Talk to your pharmacist or the person who prescribes your bisoprolol. They know you and your clinical history, they can offer you the best advice. Visit Pharmac's website www.pharmac.govt.nz/bisoprolol